Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy

Molecular Cancer Therapeutics

Volumn 3, Issue 4, 2004, Pages 459-463

  Dowlati, Afshin ^a   Nethery, David ^a   Kern, Jeffrey A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; STAT PROTEIN; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMOID TUMOR; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CELL DIVISION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TYRPHOSTINS;

EID: 4444247387     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yarden Y, Sliwkowski MX. Untangling the erbB signaling network. Nat Rev Mol Cell Biol, 2001;2:127-37.
2. Perez-Solar R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR expressing, non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001; 20:208a (abstr 831).
3. Kris MG, Natale RB, Herbst RS, et al. A phase II study of ZD1839 "Iressa" in advanced non-small cell lung cancer patients who had failed platinum and docetaxel-based regimens. Proc Am Soc Clin Oncol, 2002; 21:(abstr 1166).
4. Brognard J, Clark MS, Ni Y, Dennis PA. Akt/Protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 2001;61:3986-97.
5. Nishio K, Fukokuoka K, Fukomoto H, et al. Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells. Int J Oncol, 1999;14:461-9.
6. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel targets for therapeutic intervention. Clin Cancer Res, 2002;8:945-54.
7. Albanell J, Federico R, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol, 2001;20:110-24.
8. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human epithelial cells. Int J Cancer, 1999;83:564-70.
9. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies and cis-diammine-dichloroplatinum on well established A431 cell xenografts. Cancer Res, 1992;53:4637-42.
10. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res, 2000;6:2053-63.
11. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene, 2000;19:2489-95.
12. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor receptor and Her2/neu receptors by tyrphostins. J Biol Chem, 1993;268:11134-42.
13. Nielsen M, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci, 1997;94:6764-9.
14. Tsai CM, Gazdar AF, Venzon DJ, et al. Lack of in vitro synergy between etoposide and cis-diammine-dichloroplatinum (II). Cancer Res, 1989;49:2390-7.
15. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantification of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (Bethesda), 1994;86:1517-24.
16. Savage DG, Antman KH. Drug therapy: imatinib mesylate: a new oral targeted therapy. N Engl J Med, 2002;346:683-93.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001;344:783-92.
18. Giaconne G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol, 2002; supplement 5;abstract 4:2.
19. Sliwkowski MX, Schaefer G, Akita RW, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem, 1994;26:14661-5.
20. David M, Wong L, Flavell R, et al. STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem, 1996;271:9185-8.
21. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol, 2003;532:253-68.
22. Normanno N, Campiglio M, Somenzi G, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol, 2002;13:65-72.
23. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene, 2002;21:6255-63.